Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21 Journal Article

Authors: Gilewski, T. A.; Ragupathi, G.; Dickler, M.; Powell, S.; Bhuta, S.; Panageas, K.; Koganty, R. R.; Chin-Eng, J.; Hudis, C.; Norton, L.; Houghton, A. N.; Livingston, P. O.
Article Title: Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21
Abstract: Purpose: To determine the clinical toxicities and antibody response against sTn and tumor cells expressing sTn following immunization of high-risk breast cancer patients with clustered sTn-KLH [sTn(c)-KLH] conjugate plus QS-21. Experimental Design: Twenty-seven patients with no evidence of disease and with a history of either stage IV no evidence of disease, rising tumor markers, stage II (≥4 positive axillary nodes), or stage III disease received a total of five injections each during weeks 1, 2, 3, 7, and 19. Immunizations consisted of sTn(c)-KLH conjugate containing 30, 10, 3, or 1 μg sTn(c) plus 100 μg QS-21. Induction of IgM and IgG antibodies against synthetic sTn(c) and natural sTn on ovine submaxillary mucin were measured before and after therapy. Fluorescence-activated cell sorting analyses assessed reactivity of antibodies to LSC and MCF-7 tumor cells. Results: The most common toxicities were transient local skin reactions at the injection site and mild flu-like symptoms. All patients developed significant IgM and IgG antibody titers against sTn(c). Antibody titers against ovine submaxillary mucin were usually of lower titers. IgM reactivity with LSC tumor cells was observed in 21 patients and with MCF-7 cells in 13 patients. There was minimal IgG reactivity with LSC cells. Conclusion: Immunization with sTn(c)-KLH conjugate plus QS-21 is well tolerated and immunogenic in high-risk breast cancer patients. Future trials will incorporate sTn(c) as a component of a multiple antigen vaccine. © Aviation for Cancer Research.
Keywords: adult; clinical article; controlled study; middle aged; unclassified drug; human cell; constipation; drug tolerability; fatigue; neutropenia; cancer risk; diarrhea; side effect; adjuvant therapy; cancer staging; drug eruption; breast cancer; anemia; leukopenia; nausea; thrombocytopenia; vomiting; myalgia; herpes zoster; breast neoplasms; risk; abdominal pain; arthralgia; coughing; dyspnea; fever; injection site reaction; pruritus; goserelin; cancer vaccines; prophylaxis; tamoxifen; flu like syndrome; headache; antibodies; anastrozole; adjuvants, immunologic; dry skin; photosensitivity; immunoglobulin g antibody; urticaria; occult blood; megestrol acetate; keyhole limpet hemocyanin; immunoglobulin m antibody; immunoglobulin m; saponins; immunization; mucin; qs 21; blister; muscle rigidity; phototoxicity; immunologic agent; keyhole limpet hemocyanin plus sialyl tn; sialys tn; local skin reaction
Journal Title: Clinical Cancer Research
Volume: 13
Issue: 10
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2007-05-15
Start Page: 2977
End Page: 2985
Language: English
DOI: 10.1158/1078-0432.ccr-06-2189
PUBMED: 17504999
PROVIDER: scopus
Notes: --- - "Cited By (since 1996): 21" - "Export Date: 17 November 2011" - "CODEN: CCREF" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Clifford Hudis
    840 Hudis
  2. Larry Norton
    562 Norton
  3. Maura N Dickler
    237 Dickler
  4. Govindaswami Ragupathi
    133 Ragupathi
  5. Katherine S Panageas
    327 Panageas
  6. Alan N Houghton
    267 Houghton
  7. Shemeeakah K Powell
    4 Powell
  8. Sonal M Bhuta
    3 Bhuta